APA (7th ed.) Citation

GF, W., LF, B., D, K., T, P., JG, C., S, C., . . . B, V. T. (2021). A phase 1 clinical trial of SP16, a first-in-class anti-inflammatory LRP1 agonist, in healthy volunteers. PloS one, 16(5), e0247357. https://doi.org/10.1371/journal.pone.0247357

Chicago Style (17th ed.) Citation

GF, Wohlford, et al. "A Phase 1 Clinical Trial of SP16, a First-in-class Anti-inflammatory LRP1 Agonist, in Healthy Volunteers." PloS One 16, no. 5 (2021): e0247357. https://doi.org/10.1371/journal.pone.0247357.

MLA (9th ed.) Citation

GF, Wohlford, et al. "A Phase 1 Clinical Trial of SP16, a First-in-class Anti-inflammatory LRP1 Agonist, in Healthy Volunteers." PloS One, vol. 16, no. 5, 2021, p. e0247357, https://doi.org/10.1371/journal.pone.0247357.